Overview
ImpediMed received FDA 510(k) clearance for sarcopenia risk assessment using its SOZO Digital Health Platform.
SOZO becomes the only FDA-cleared bioimpedance spectroscopy (BIS) solution for clinical assessment of sarcopenia risk.
The new capability could help clinicians identify muscle loss earlier, particularly in cancer patients undergoing treatment.
The News
ImpediMed has received FDA 510(k) clearance to use its SOZO Digital Health Platform for assessing patients at risk of sarcopenia, a condition involving low or declining muscle mass. The clearance expands SOZO’s clinical utility beyond its existing applications in fluid and body composition monitoring.
The platform uses bioimpedance spectroscopy (BIS) to generate muscle-mass indices through the same scan already used by oncology teams for lymphedema monitoring and body composition assessment. The quick, non-invasive measurement provides immediate results, allowing clinicians to track changes in muscle health over time without relying on repeated DXA or CT scans.
Sarcopenia affects roughly one in three breast cancer patients during chemotherapy and is also associated with conditions including heart failure, type 2 diabetes, and obesity. In oncology, muscle loss can remain hidden despite stable weight or normal BMI and has been linked to poorer treatment tolerance and outcomes.
The sarcopenia capability will be introduced through SOZO software release v6.3, expected in fall 2026.
Industry Perspective
Sarcopenia remains an underrecognized complication of cancer and chronic disease, while conventional assessment methods such as DXA and CT are not designed for frequent monitoring. As healthcare increasingly focuses on early intervention and longitudinal care, accessible technologies that can track muscle health during routine visits could help clinicians identify patients who need nutritional or exercise interventions sooner.
Strategic Impact
The FDA clearance broadens SOZO’s role in clinical body composition monitoring and strengthens ImpediMed’s position in oncology and chronic disease management. By adding sarcopenia risk assessment to an existing point-of-care workflow, SOZO could enable earlier identification of muscle loss and support timely interventions aimed at maintaining treatment tolerance, recovery, and overall patient outcomes.
Source: PRnewswire
